{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T18:47:39Z","timestamp":1772650059210,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T00:00:00Z","timestamp":1730592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T00:00:00Z","timestamp":1730592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Hungarian National Research, Development and Innovation Office","award":["N-OTKA 114460"],"award-info":[{"award-number":["N-OTKA 114460"]}]},{"name":"Hungarian National Research, Development and Innovation Office","award":["K-135540"],"award-info":[{"award-number":["K-135540"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-77285-x","type":"journal-article","created":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T18:01:53Z","timestamp":1730656913000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Identification of genetic fingerprint of type I interferon therapy in visceral metastases of melanoma"],"prefix":"10.1038","volume":"14","author":[{"given":"Laura","family":"V\u00edzkeleti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orsolya","family":"Papp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikt\u00f3ria","family":"Doma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeovanis","family":"Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gy\u00f6rgy","family":"Mark\u00f3-Varga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szonja A.","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bal\u00e1zs","family":"Gy\u0151rffy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarolta","family":"K\u00e1rp\u00e1ti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f3zsef","family":"T\u00edm\u00e1r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,3]]},"reference":[{"key":"77285_CR1","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.3389\/fimmu.2018.02061","volume":"9","author":"AJ Lee","year":"2018","unstructured":"Lee, A. J. & Ashkar, A. A. The dual nature of type I and type II interferons. Front. Immunol.  9, 2061. https:\/\/doi.org\/10.3389\/fimmu.2018.02061 (2018).","journal-title":"Front. Immunol."},{"key":"77285_CR2","doi-asserted-by":"publisher","first-page":"D1040","DOI":"10.1093\/nar\/gks1215","volume":"41","author":"I Rusinova","year":"2013","unstructured":"Rusinova, I. et al. Interferome v2.0: an updated database of annotated interferon-regulated genes. Nucleic Acids Res. 41, D1040-1046. https:\/\/doi.org\/10.1093\/nar\/gks1215 (2013).","journal-title":"Nucleic Acids Res."},{"key":"77285_CR3","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.exphem.2010.03.005","volume":"38","author":"M Lu","year":"2010","unstructured":"Lu, M. et al. Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. Exp. Hematol. 38, 472\u2013480. https:\/\/doi.org\/10.1016\/j.exphem.2010.03.005 (2010).","journal-title":"Exp. Hematol."},{"key":"77285_CR4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nri3845","volume":"15","author":"L Zitvogel","year":"2015","unstructured":"Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J. & Kroemer, G. Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15, 405\u2013414. https:\/\/doi.org\/10.1038\/nri3845 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"77285_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.573141","volume":"10","author":"K Kang","year":"2020","unstructured":"Kang, K., Xie, F., Mao, J., Bai, Y. & Wang, X. Significance of tumor mutation burden in immune infiltration and prognosis in cutaneous melanoma. Front. Oncol. 10, 573141. https:\/\/doi.org\/10.3389\/fonc.2020.573141 (2020).","journal-title":"Front. Oncol."},{"key":"77285_CR6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.cytogfr.2014.11.008","volume":"26","author":"R Di Trolio","year":"2015","unstructured":"Di Trolio, R., Simeone, E., Di Lorenzo, G., Buonerba, C. & Ascierto, P. A. The use of interferon in melanoma patients: a systematic review. Cytokine Growth Factor Rev. 26, 203\u2013212. https:\/\/doi.org\/10.1016\/j.cytogfr.2014.11.008 (2015).","journal-title":"Cytokine Growth Factor Rev."},{"key":"77285_CR7","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s41591-020-01211-7","volume":"27","author":"EA Rozeman","year":"2021","unstructured":"Rozeman, E. A. et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat. Med. 27, 256\u2013263. https:\/\/doi.org\/10.1038\/s41591-020-01211-7 (2021).","journal-title":"Nat. Med."},{"key":"77285_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1054\/bjoc.2001.1865","volume":"85","author":"U Certa","year":"2001","unstructured":"Certa, U., Seiler, M., Padovan, E. & Spagnoli, G. C. High density oligonucleotide array analysis of interferon- alpha2a sensitivity and transcriptional response in melanoma cells. Br. J. Cancer. 85, 107\u2013114. https:\/\/doi.org\/10.1054\/bjoc.2001.1865 (2001).","journal-title":"Br. J. Cancer"},{"key":"77285_CR9","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/j.0022-202X.2004.23433.x","volume":"123","author":"C Krepler","year":"2004","unstructured":"Krepler, C. et al. Pegylated and conventional interferon-alpha induce comparable transcriptional responses and inhibition of tumor growth in a human melanoma SCID mouse xenotransplantation model. J. Investig. Dermatol. 123, 664\u2013669. https:\/\/doi.org\/10.1111\/j.0022-202X.2004.23433.x (2004).","journal-title":"J. Investig. Dermatol."},{"key":"77285_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.celrep.2016.03.006","volume":"15","author":"YV Katlinskaya","year":"2016","unstructured":"Katlinskaya, Y. V. et al. Suppression of type I interferon signaling overcomes oncogene-induced senescence and mediates melanoma development and progression. Cell Rep. 15, 171\u2013180. https:\/\/doi.org\/10.1016\/j.celrep.2016.03.006 (2016).","journal-title":"Cell Rep."},{"key":"77285_CR11","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","volume":"167","author":"J Gao","year":"2016","unstructured":"Gao, J. et al. Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell. 167, 397-404.e399. https:\/\/doi.org\/10.1016\/j.cell.2016.08.069 (2016).","journal-title":"Cell"},{"key":"77285_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1471-2407-7-34","volume":"7","author":"T Rodriguez","year":"2007","unstructured":"Rodriguez, T. et al. Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines. BMC Cancer. 7, 34. https:\/\/doi.org\/10.1186\/1471-2407-7-34 (2007).","journal-title":"BMC Cancer"},{"key":"77285_CR13","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3389\/fimmu.2018.01414","volume":"9","author":"S Alavi","year":"2018","unstructured":"Alavi, S. et al. Interferon signaling is frequently downregulated in melanoma. Front Immunol. 9, 1414. https:\/\/doi.org\/10.3389\/fimmu.2018.01414 (2018).","journal-title":"Front Immunol"},{"key":"77285_CR14","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3389\/fimmu.2020.00542","volume":"11","author":"AC Buzzai","year":"2020","unstructured":"Buzzai, A. C. et al. Diverse anti-tumor immune potential driven by individual IFNalpha subtypes. Front. Immunol. 11, 542. https:\/\/doi.org\/10.3389\/fimmu.2020.00542 (2020).","journal-title":"Front. Immunol."},{"key":"77285_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0146325","volume":"11","author":"R Heise","year":"2016","unstructured":"Heise, R. et al. Interferon alpha signalling and its relevance for the upregulatory effect of transporter proteins associated with antigen processing (TAP) in patients with malignant melanoma. PLoS ONE. 11, e0146325. https:\/\/doi.org\/10.1371\/journal.pone.0146325 (2016).","journal-title":"PLoS ONE"},{"key":"77285_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052704","author":"A Ladanyi","year":"2022","unstructured":"Ladanyi, A. et al. Identification of a tumor cell associated type I IFN resistance gene expression signature of human melanoma, the components of which have a predictive potential for immunotherapy. Int. J. Mol. Sci.  https:\/\/doi.org\/10.3390\/ijms23052704 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"77285_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.473","volume":"11","author":"LH Betancourt","year":"2021","unstructured":"Betancourt, L. H. et al. The human melanoma proteome atlas-defining the molecular pathology. Clin Transl. Med. 11, e473. https:\/\/doi.org\/10.1002\/ctm2.473 (2021).","journal-title":"Clin Transl. Med."},{"key":"77285_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.451","volume":"11","author":"LH Betancourt","year":"2021","unstructured":"Betancourt, L. H. et al. The human melanoma proteome atlas-complementing the melanoma transcriptome. Clin. Transl. Med. 11, e451. https:\/\/doi.org\/10.1002\/ctm2.451 (2021).","journal-title":"Clin. Transl. Med."},{"key":"77285_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13236066","author":"J Gil","year":"2021","unstructured":"Gil, J. et al. An observational study on the molecular profiling of primary melanomas reveals a progression dependence on mitochondrial activation. Cancers. https:\/\/doi.org\/10.3390\/cancers13236066 (2021).","journal-title":"Cancers"},{"key":"77285_CR20","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1186\/s12885-019-5990-9","volume":"19","author":"V Doma","year":"2019","unstructured":"Doma, V., Karpati, S., Raso, E., Barbai, T. & Timar, J. Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma. BMC Cancer. 19, 786. https:\/\/doi.org\/10.1186\/s12885-019-5990-9 (2019).","journal-title":"BMC Cancer"},{"key":"77285_CR21","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkad1025","volume":"52","author":"M Milacic","year":"2024","unstructured":"Milacic, M. et al. The Reactome Pathway Knowledgebase 2024. Nucleic Acids Res.  52, D672\u2013D678. https:\/\/doi.org\/10.1093\/nar\/gkad1025 (2024).","journal-title":"Nucleic Acids Res."},{"key":"77285_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13235984","author":"O Papp","year":"2021","unstructured":"Papp, O. et al. Organ specific copy number variations in visceral metastases of human melanoma. Cancers.  https:\/\/doi.org\/10.3390\/cancers13235984 (2021).","journal-title":"Cancers"},{"key":"77285_CR23","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s10555-023-10087-1","volume":"42","author":"J Timar","year":"2023","unstructured":"Timar, J., Honn, K. V., Hendrix, M. J. C., Marko-Varga, G. & Jalkanen, S. Newly identified form of phenotypic plasticity of cancer: immunogenic mimicry. Cancer Metastasis Rev. 42, 323\u2013334. https:\/\/doi.org\/10.1007\/s10555-023-10087-1 (2023).","journal-title":"Cancer Metastasis Rev."},{"key":"77285_CR24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.intimp.2013.12.010","volume":"18","author":"LF Marchi","year":"2014","unstructured":"Marchi, L. F., Sesti-Costa, R., Ignacchiti, M. D., Chedraoui-Silva, S. & Mantovani, B. In vitro activation of mouse neutrophils by recombinant human interferon-gamma: increased phagocytosis and release of reactive oxygen species and pro-inflammatory cytokines. Int. Immunopharmacol. 18, 228\u2013235. https:\/\/doi.org\/10.1016\/j.intimp.2013.12.010 (2014).","journal-title":"Int. Immunopharmacol."},{"key":"77285_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/genes13122332","author":"E Ermis Akyuz","year":"2022","unstructured":"Ermis Akyuz, E. & Bell, S. M. The diverse role of CUB and Sushi Multiple Domains 1 (CSMD1) in human diseases. Genes. https:\/\/doi.org\/10.3390\/genes13122332 (2022).","journal-title":"Genes"},{"key":"77285_CR26","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1038\/s41467-018-05286-2","volume":"9","author":"D Li","year":"2018","unstructured":"Li, D. et al. Armadillo repeat containing 12 promotes neuroblastoma progression through interaction with retinoblastoma binding protein 4. Nat. Commun. 9, 2829. https:\/\/doi.org\/10.1038\/s41467-018-05286-2 (2018).","journal-title":"Nat. Commun."},{"key":"77285_CR27","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1158\/0008-5472.CAN-19-2373","volume":"80","author":"N Vandamme","year":"2020","unstructured":"Vandamme, N. et al. The EMT transcription factor ZEB2 promotes proliferation of primary and metastatic melanoma while suppressing an invasive, mesenchymal-like phenotype. Cancer Res. 80, 2983\u20132995. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-2373 (2020).","journal-title":"Cancer Res."},{"key":"77285_CR28","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1093\/neuonc\/noq158","volume":"13","author":"J Barrow","year":"2011","unstructured":"Barrow, J. et al. Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas. Neuro Oncol. 13, 212\u2013222. https:\/\/doi.org\/10.1093\/neuonc\/noq158 (2011).","journal-title":"Neuro Oncol."},{"key":"77285_CR29","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.neo.2018.02.009","volume":"20","author":"L Mologni","year":"2018","unstructured":"Mologni, L. et al. Concomitant BCORL1 and BRAF mutations in vemurafenib-resistant melanoma cells. Neoplasia. 20, 467\u2013477. https:\/\/doi.org\/10.1016\/j.neo.2018.02.009 (2018).","journal-title":"Neoplasia"},{"key":"77285_CR30","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1158\/0008-5472.CAN-19-0040","volume":"79","author":"MF Emmons","year":"2019","unstructured":"Emmons, M. F. et al. HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy. Cancer Res. 79, 2947\u20132961. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-0040 (2019).","journal-title":"Cancer Res."},{"key":"77285_CR31","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10549-020-06035-0","volume":"186","author":"E Klaestad","year":"2021","unstructured":"Klaestad, E. et al. ZNF703 gene copy number and protein expression in breast cancer; associations with proliferation, prognosis and luminal subtypes. Breast Cancer Res. Treat. 186, 65\u201377. https:\/\/doi.org\/10.1007\/s10549-020-06035-0 (2021).","journal-title":"Breast Cancer Res. Treat."},{"key":"77285_CR32","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jid.2016.08.024","volume":"137","author":"V Lucarini","year":"2017","unstructured":"Lucarini, V. et al. Combining type I interferons and 5-Aza-2\u2019-deoxycitidine to improve anti-tumor response against melanoma. J. Investig. Dermatol. 137, 159\u2013169. https:\/\/doi.org\/10.1016\/j.jid.2016.08.024 (2017).","journal-title":"J. Investig. Dermatol."},{"key":"77285_CR33","doi-asserted-by":"publisher","first-page":"4455","DOI":"10.1158\/0008-5472.CAN-21-0772","volume":"81","author":"JR White","year":"2021","unstructured":"White, J. R. et al. AP-2alpha-mediated activation of E2F and EZH2 drives melanoma metastasis. Cancer Res. 81, 4455\u20134470. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-0772 (2021).","journal-title":"Cancer Res."},{"key":"77285_CR34","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/s41419-020-03141-1","volume":"11","author":"S Zhang","year":"2020","unstructured":"Zhang, S., Wan, H. & Zhang, X. LncRNA LHFPL3-AS1 contributes to tumorigenesis of melanoma stem cells via the miR-181a-5p\/BCL2 pathway. Cell Death Dis. 11, 950. https:\/\/doi.org\/10.1038\/s41419-020-03141-1 (2020).","journal-title":"Cell Death Dis."},{"key":"77285_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10555-021-09955-5","volume":"40","author":"G Tigyi","year":"2021","unstructured":"Tigyi, G. et al. Anti-cancer strategies targeting the autotaxin-lysophosphatidic acid receptor axis: is there a path forward?. Cancer Metastasis Rev. 40, 3\u20135. https:\/\/doi.org\/10.1007\/s10555-021-09955-5 (2021).","journal-title":"Cancer Metastasis Rev."},{"issue":"Suppl","key":"77285_CR36","doi-asserted-by":"publisher","first-page":"C114","DOI":"10.4103\/0973-1482.145816","volume":"10","author":"C Huang","year":"2014","unstructured":"Huang, C., Sheng, Y., Jia, J. & Chen, L. Identification of melanoma biomarkers based on network modules by integrating the human signaling network with microarrays. J. Cancer Res. Ther. 10(Suppl), C114-124. https:\/\/doi.org\/10.4103\/0973-1482.145816 (2014).","journal-title":"J. Cancer Res. Ther."},{"key":"77285_CR37","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1158\/0008-5472.CAN-22-0283","volume":"82","author":"X Xu","year":"2022","unstructured":"Xu, X. et al. Gain of Chromosome 1q perturbs a competitive endogenous RNA network to promote melanoma metastasis. Cancer Res. 82, 3016\u20133031. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-0283 (2022).","journal-title":"Cancer Res."},{"key":"77285_CR38","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/pcmr.12378","volume":"28","author":"S Romano","year":"2015","unstructured":"Romano, S. et al. Immunomodulatory pathways regulate expression of a spliced FKBP51 isoform in lymphocytes of melanoma patients. Pigment Cell Melanoma Res. 28, 442\u2013452. https:\/\/doi.org\/10.1111\/pcmr.12378 (2015).","journal-title":"Pigment Cell Melanoma Res."},{"key":"77285_CR39","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.bbrc.2019.12.042","volume":"523","author":"J Ke","year":"2020","unstructured":"Ke, J. et al. Melanoma migration is promoted by prion protein via Akt-hsp27 signaling axis. Biochem. Biophys. Res. Commun. 523, 375\u2013381. https:\/\/doi.org\/10.1016\/j.bbrc.2019.12.042 (2020).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"77285_CR40","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/CMR.0000000000000803","volume":"32","author":"J Xu","year":"2022","unstructured":"Xu, J. et al. LINC01063 functions as an oncogene in melanoma through regulation of miR-5194-mediated SOX12 expression. Melanoma Res. 32, 218\u2013230. https:\/\/doi.org\/10.1097\/CMR.0000000000000803 (2022).","journal-title":"Melanoma Res."},{"key":"77285_CR41","doi-asserted-by":"publisher","first-page":"14607","DOI":"10.1038\/ncomms14607","volume":"8","author":"K Takeda","year":"2017","unstructured":"Takeda, K. et al. IFN-gamma is required for cytotoxic T cell-dependent cancer genome immunoediting. Nat. Commun. 8, 14607. https:\/\/doi.org\/10.1038\/ncomms14607 (2017).","journal-title":"Nat. Commun."},{"key":"77285_CR42","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s43018-020-0036-4","volume":"1","author":"ME Hoekstra","year":"2020","unstructured":"Hoekstra, M. E. et al. Long-distance modulation of bystander tumor cells by CD8(+) T cell-secreted IFNgamma. Nat. Cancer. 1, 291\u2013301. https:\/\/doi.org\/10.1038\/s43018-020-0036-4 (2020).","journal-title":"Nat. Cancer"},{"key":"77285_CR43","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s43018-020-0038-2","volume":"1","author":"R Thibaut","year":"2020","unstructured":"Thibaut, R. et al. Bystander IFN-gamma activity promotes widespread and sustained cytokine signaling altering the tumor microenvironment. Nat. Cancer. 1, 302\u2013314. https:\/\/doi.org\/10.1038\/s43018-020-0038-2 (2020).","journal-title":"Nat. Cancer"},{"key":"77285_CR44","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1158\/2643-3230.BCD-21-0115","volume":"3","author":"EJ Schaefer","year":"2022","unstructured":"Schaefer, E. J. et al. BCOR and BCORL1 mutations drive epigenetic reprogramming and oncogenic signaling by unlinking PRC1.1 from target genes. Blood Cancer Discov. 3, 116\u2013135. https:\/\/doi.org\/10.1158\/2643-3230.BCD-21-0115 (2022).","journal-title":"Blood Cancer Discov."},{"key":"77285_CR45","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jaut.2016.05.012","volume":"73","author":"J Meng","year":"2016","unstructured":"Meng, J. et al. Rb selectively inhibits innate IFN-beta production by enhancing deacetylation of IFN-beta promoter through HDAC1 and HDAC8. J. Autoimmun. 73, 42\u201353. https:\/\/doi.org\/10.1016\/j.jaut.2016.05.012 (2016).","journal-title":"J. Autoimmun."},{"key":"77285_CR46","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1158\/2159-8290.CD-13-0458","volume":"4","author":"T Bald","year":"2014","unstructured":"Bald, T. et al. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov. 4, 674\u2013687. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0458 (2014).","journal-title":"Cancer Discov."},{"key":"77285_CR47","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/ijc.34602","volume":"153","author":"A Fragale","year":"2023","unstructured":"Fragale, A. et al. Reversing vemurafenib-resistance in primary melanoma cells by combined romidepsin and type I IFN treatment through blocking of tumorigenic signals and induction of immunogenic effects. Int. J. Cancer. 153, 1080\u20131095. https:\/\/doi.org\/10.1002\/ijc.34602 (2023).","journal-title":"Int. J. Cancer"},{"key":"77285_CR48","doi-asserted-by":"publisher","first-page":"1249330","DOI":"10.3389\/fimmu.2023.1249330","volume":"14","author":"A Razaghi","year":"2023","unstructured":"Razaghi, A., Durand-Dubief, M., Brusselaers, N. & Bjornstedt, M. Combining PD-1\/PD-L1 blockade with type I interferon in cancer therapy. Front. Immunol. 14, 1249330. https:\/\/doi.org\/10.3389\/fimmu.2023.1249330 (2023).","journal-title":"Front. Immunol."},{"key":"77285_CR49","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.gdata.2014.06.007","volume":"2","author":"DM Marzese","year":"2014","unstructured":"Marzese, D. M., Huynh, J. L., Kawas, N. P. & Hoon, D. S. Multi-platform genome-wide analysis of melanoma progression to brain metastasis. Genom. Data. 2, 150\u2013152. https:\/\/doi.org\/10.1016\/j.gdata.2014.06.007 (2014).","journal-title":"Genom. Data"},{"key":"77285_CR50","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41416-020-01090-2","volume":"124","author":"R Rabbie","year":"2021","unstructured":"Rabbie, R. et al. The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence. Br. J. Cancer. 124, 156\u2013160. https:\/\/doi.org\/10.1038\/s41416-020-01090-2 (2021).","journal-title":"Br. J. Cancer"},{"key":"77285_CR51","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s12967-019-2039-4","volume":"17","author":"A Manca","year":"2019","unstructured":"Manca, A. et al. Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach. J. Transl. Med. 17, 289. https:\/\/doi.org\/10.1186\/s12967-019-2039-4 (2019).","journal-title":"J. Transl. Med."},{"key":"77285_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35103","author":"A Forschner","year":"2024","unstructured":"Forschner, A. et al. Response and outcome of patients with melanoma skin metastases and immune checkpoint inhibition. Int. J. Cancer. https:\/\/doi.org\/10.1002\/ijc.35103 (2024).","journal-title":"Int. J. Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77285-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77285-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77285-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T18:02:05Z","timestamp":1730656925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77285-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,3]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["77285"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-77285-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,3]]},"assertion":[{"value":"17 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26540"}}